Avidity Biosciences (NASDAQ:RNA) Given Overweight Rating at Wells Fargo & Company
Wells Fargo & Company reissued their overweight rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $50.00 target price on the biotechnology company’s stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $35.00 price […]
More Stories
Scott Kingsley Swift: Taylor Swift’s Father – Net Worth, &, Career
Scott Kingsley Swift is one of the most widely known individuals in America, popularly recognized as heartthrob musician Taylor Swift’s...
Imperial Metals (OTCMKTS:IPMLF) Stock Price Down 0.8% – Should You Sell?
Imperial Metals Co. (OTCMKTS:IPMLF – Get Free Report) shares traded down 0.8% during trading on Tuesday . The stock traded...
The Future of AI in Entertainment: How AI Is Changing Online Casinos, Gaming, and Streaming
The entertainment sector is quickly changing with the integration of Artificial Intelligence (AI) by more and more companies – from...
J Heath Deneke Sells 1,000 Shares of Summit Midstream Corporation (NYSE:SMC) Stock
Summit Midstream Corporation (NYSE:SMC – Get Free Report) CEO J Heath Deneke sold 1,000 shares of the firm’s stock in...
Incyte Co. (NASDAQ:INCY) Receives Average Rating of “Hold” from Brokerages
Incyte Co. (NASDAQ:INCY – Get Free Report) has been assigned an average recommendation of “Hold” from the twenty ratings firms...
Eaton Co. plc (NYSE:ETN) Receives Average Rating of “Moderate Buy” from Brokerages
Eaton Co. plc (NYSE:ETN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen...